Corporate Profile

Company GeneFrontier Corporation
Established October 13, 2010
Capital 10 million yen
Board of Directors
CEO Masanobu Sugawara
COO Takashi Ebihara
Director Masaru Mitsuda
Auditor Kazuya Hasegawa
Shareholders KANEKA Corporation

1. Providing innovative research products, services and technologies in protein engineering and drug discovery.
– Customized Human Monoclonal Antibody Generation service, partnered with Bio-Rad.
– PUREfrex®, reconstituted cell-free protein synthesis system.
– PUREfrex® RD, ribosome display utilizing PUREfrex®.

2. Development of Novel Biologics including Therapeutic Monoclonal Antibody.

Contact SHARP Kashiwa Building, 4F
273-1 Kashiwa, Kashiwa-shi, Chiba 277-0005, Japan
E-mail Please contact here